Cagrilintide Testing
MW: ~3800 g/molHalf-life: ~7 days
Long-acting amylin analog; commonly co-formulated with semaglutide as CagriSema.
Mechanism of action
Long-acting amylin analog (the short-acting analog is pramlintide / Symlin). Binds amylin and calcitonin receptors to delay gastric emptying, suppress glucagon, and produce satiety. Co-formulated with semaglutide as CagriSema; combined effect is additive on weight loss.
Research areas
- ●Obesity (Phase 3)
- ●Type 2 diabetes
- ●Combination therapy with GLP-1 RAs
What we test on Cagrilintide
RP-HPLC purity, intact-mass LC-MS, disulfide bond confirmation by non-reducing tryptic mapping, aggregation by SEC.
Standard GLP-1 / Metabolic Panel
- ✓RP-HPLC purity (UV 214 nm)
- ✓LC-MS/MS identity (Orbitrap)
- ✓Counter-ion / residual TFA
- ✓Water content (KF)
- ✓Endotoxin (LAL, USP <85>)
Common impurities & failure modes
- Linear (uncyclized) precursor
+2 Da vs. main peak; the most important impurity to quantify on cyclic peptides.
- Misfolded disulfide isomers
When other Cys residues are present, scrambled disulfides can form. LC-MS with non-reducing conditions resolves.
- Aggregates
Common in lipidated amylin analogs.
Related GLP-1 / Metabolic peptides
Adipotide
2611.13 g/mol
Proapoptotic peptide targeting white-adipose vasculature.
AOD-9604
1815.08 g/mol
C-terminal hGH fragment (aa 176-191) studied for lipolysis.
Orforglipron
~760 g/mol
Small-molecule, oral GLP-1 receptor agonist in late-stage development.
Retatrutide
4177.63 g/mol
Triple agonist targeting GIP, GLP-1, and glucagon receptors (LY3437943). In Phase 3 for obesity.
Semaglutide
4113.58 g/mol
GLP-1 receptor agonist with extended half-life via a C18 diacid albumin-binding chain. The branded versions are Ozempic and Wegovy.
Tesofensine
327.25 g/mol
Small-molecule SNDRI studied for obesity. Phase 3 ongoing.